105 related articles for article (PubMed ID: 26395450)
1. Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Allendorf DJ; Bordoni RE; Grant SC; Saleh MN; Reddy VB; Jerome ML; Dixon PM; Miley DK; Singh KP; Robert F
Cancer Chemother Pharmacol; 2015 Nov; 76(5):949-55. PubMed ID: 26395450
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Rossman J; Reddy V; Cantor A; Miley D; Robert F
Lung Cancer; 2011 May; 72(2):219-23. PubMed ID: 20934233
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer.
Lee HS; Lee YG; Koo DH; Oh S; Nam H; Song JU; Lim SY; Lim SY; Lee SS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):933-7. PubMed ID: 26374553
[TBL] [Abstract][Full Text] [Related]
5. A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.
Okishio K; Mio T; Kawahara M; Yoshioka H; Yanagihara K; Daimon T; Furuse K
Jpn J Clin Oncol; 2012 May; 42(5):387-93. PubMed ID: 22430871
[TBL] [Abstract][Full Text] [Related]
6. Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer.
Schmittel A; Schulze K; Hütter G; Krebs P; Thiel E; Keilholz U
Onkologie; 2004 Jun; 27(3):280-4. PubMed ID: 15249718
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.
Sato M; Ando M; Minami H; Ando Y; Ando M; Yamamoto M; Sakai S; Watanabe A; Ikeda T; Sekido Y; Saka H; Shimokata K; Hasegawa Y
Cancer Chemother Pharmacol; 2001 Dec; 48(6):481-7. PubMed ID: 11800029
[TBL] [Abstract][Full Text] [Related]
9. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer.
Johnson FM; Kurie JM; Peeples BO; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):17-21. PubMed ID: 12886869
[TBL] [Abstract][Full Text] [Related]
10. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
[TBL] [Abstract][Full Text] [Related]
11. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
Oh IJ; Kim KS; Park CK; Kim YC; Lee KH; Jeong JH; Kim SY; Lee JE; Shin KC; Jang TW; Lee HK; Lee KY; Lee SY
BMC Cancer; 2016 Aug; 16(1):690. PubMed ID: 27566413
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer.
Fukuda M; Soda H; Soejima Y; Fukuda M; Kinoshita A; Takatani H; Kasai T; Nagashima S; Kawabata S; Doi S; Kohno S; Oka M
Cancer Chemother Pharmacol; 2006 Nov; 58(5):601-6. PubMed ID: 16463061
[TBL] [Abstract][Full Text] [Related]
13. Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.
Charpidou A; Tsagouli S; Tsimpoukis S; Vassias A; Makrilia N; Stratakos G; Gkiozos I; Syrigos K
Anticancer Drugs; 2010 Jul; 21(6):651-5. PubMed ID: 20386306
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.
Hermes A; Bergman B; Bremnes R; Ek L; Fluge S; Sederholm C; Sundstrøm S; Thaning L; Vilsvik J; Aasebø U; Sörenson S
J Clin Oncol; 2008 Sep; 26(26):4261-7. PubMed ID: 18779613
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer.
Köster W; Heider A; Niederle N; Wilke H; Stamatis G; Fischer JR; Koch JA; Stahl M
J Thorac Oncol; 2007 Apr; 2(4):312-6. PubMed ID: 17409803
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer.
Harada T; Hamada A; Shimokawa M; Takayama K; Kudoh S; Maeno K; Saeki S; Miyawaki H; Moriyama A; Nakagawa K; Nakanishi Y
Jpn J Clin Oncol; 2014 Feb; 44(2):127-33. PubMed ID: 24379211
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer.
Sohn JH; Choi HJ; Chang J; Kim SK; Lee CG; Chung KY; Kim DJ; Cho BC; Shin SJ; Moon YW; Kim JH
Lung Cancer; 2006 Dec; 54(3):365-70. PubMed ID: 17011068
[TBL] [Abstract][Full Text] [Related]
19. A feasibility study of carboplatin plus irinotecan treatment for elderly patients with extensive disease small-cell lung cancer.
Misumi Y; Nishio M; Takahashi T; Ohyanagi F; Horiike A; Murakami H; Kenmotsu H; Yamamoto N; Ishii M; Shimokawa T; Hida N; Okamoto H
Jpn J Clin Oncol; 2014 Feb; 44(2):116-21. PubMed ID: 24338555
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
